Annovis Bio(ANVS)

Focus: Annovis Bio is a specialty pharmaceutical company focused on neurodegenerative diseases, primarily Alzheimer's and Parkinson's disease, with a pipeline centered on its lead candidate buntanetap/posiphen. The company is publicly traded but pre-revenue with minimal cash reserves.

Neurology Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Annovis Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Annovis Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

Pipeline & Clinical Trials

Posiphen® tartrate capsules

Alzheimer's Disease

Phase 1

Posiphen

Alzheimer Disease

Phase 1/2

Posiphen

Help build intelligence for Annovis Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage neurology focus with Phase 3 programs in high-need indications (Alzheimer's, Parkinson's) offers exposure to transformative science
Public company status provides equity upside and career credibility vs. private biotech
Lean structure ($20M R&D spend FY2025) means high visibility and direct impact on company strategy

Watch Out For

Critical cash burn with only $11M cash on hand (FY2025) against $20M R&D spend signals runway pressure and potential dilution or restructuring risk
Zero active job openings and declining R&D budget ($39M → $20M YoY) indicate contraction, not expansion
Pre-revenue status with no approved products means zero commercial revenue to fund operations; company depends entirely on capital markets or partnership deals

Generated by Claude from Annovis Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Buntanetap/Posiphen

Alzheimer Disease

Phase 2/3

buntanetap/posiphen

Parkinson's Disease (PD)

Phase 2/3

buntanetap/posiphen

Early Alzheimers Disease

Phase 3

buntanetap/posiphen

Parkinson's Disease, Idiopathic

Phase 3